MEDPLUSMedplus Health Services Limited
Pharma · Pharmaceutical Retailers · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing services, as well as contract manufacturing of private-label pharmaceuticals, wellness products, and FMCG goods; and operates diagnostic centres. It distributes its products through retail and online channels. The company was incorporated in 2006 and is based in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
Why avoid
- • Overall evidence is weak (AlgoScore 37/100)
- • ROCE: 9.5%
- • Dividend yield: 0.00%
- • RSI: 34
- • MACD: bearish
⚖️ 1 bullish pattern setup is currently active on this stock. Pattern setup-quality percentages measure how cleanly a chart formation developed — they are not an endorsement of the company. Short-term traders may still trade those setups with strict stops; the AVOID verdict reflects the overall risk/fundamental profile for holding.
Bull case
- • Revenue growth: 23.5% YoY
- • Profit growth: 24.1% YoY
- • Debt/Equity: 0.72
- • Trend strength (ADX): 37
Bear case
- • ROCE: 9.5%
- • Dividend yield: 0.00%
- • RSI: 34
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • ROCE: 9.5%
- • Dividend yield: 0.00%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹15.05). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.